These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30041608)

  • 1. Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study.
    Jing J; Yinchen S; Xia C; Jing W; Chong C; Xun X; Hengye H; Kun L
    BMC Ophthalmol; 2018 Jul; 18(1):181. PubMed ID: 30041608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
    Lu X; Sun X
    Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
    Nguyen TT; Guymer R
    Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Jin E; Bai Y; Luo L; Huang L; Zhu X; Ding X; Qi H; Zhao M
    Retina; 2017 May; 37(5):971-977. PubMed ID: 27617537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and network meta-analysis.
    Tricco AC; Thomas SM; Lillie E; Veroniki AA; Hamid JS; Pham B; Lee T; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Janoudi G; Muni RH; Francisconi CLM; Richter T; Straus SE
    Syst Rev; 2021 Dec; 10(1):315. PubMed ID: 34930439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Efficacy and Safety between Conbercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: A Meta-Analysis of Randomized Controlled Trials.
    Wang X; Yu C; Yang J; Liu Y; Xu Y; Li W
    Ophthalmic Res; 2022; 65(2):140-151. PubMed ID: 34583363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept.
    Liu H; Ma Y; Xu HC; Huang LY; Zhai LY; Zhang XR
    Curr Eye Res; 2020 Dec; 45(12):1467-1476. PubMed ID: 32631094
    [No Abstract]   [Full Text] [Related]  

  • 8. PREDICTORS OF ONE-YEAR VISUAL OUTCOMES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Kodjikian L; Decullier E; Souied EH; Roux A; Aulagner G; Huot L;
    Retina; 2018 Aug; 38(8):1492-1499. PubMed ID: 28654629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis.
    Cui C; Lu H
    Clin Interv Aging; 2018; 13():51-62. PubMed ID: 29343949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis.
    Wang L; Zhang C; Hua R
    Drug Des Devel Ther; 2018; 12():3625-3633. PubMed ID: 30464394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
    BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study.
    Li X; Xu G; Wang Y; Xu X; Liu X; Tang S; Zhang F; Zhang J; Tang L; Wu Q; Luo D; Ke X;
    Ophthalmology; 2014 Sep; 121(9):1740-7. PubMed ID: 24793528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
    Rahimy E; Rayess N; Ho AC; Regillo CD
    Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.
    Vogel RN; Davis DB; Kimura BH; Rathinavelu S; Graves GS; Szabo A; Han DP
    Retina; 2017 Feb; 37(2):257-264. PubMed ID: 27429385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical Dorzolamide-Timolol With Intravitreous Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration.
    Sridhar J; Hsu J; Shahlaee A; Garg SJ; Spirn MJ; Fineman MS; Vander J
    JAMA Ophthalmol; 2016 Apr; 134(4):437-43. PubMed ID: 26914218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.